In the retrospective series by Brodska et al., high PD-L1 expression in AML blasts predicted inferior survival outcomes, though this negative prognostic impact was limited to the patient subgroup affected with NPM1-mutated AML showing concurrent FLT3-ITD [71]. The gene discussed is FLT3; the disease is acute myeloid leukemia.